Review
Jul 2026
Next-Generation Checkpoint Combinations: Optimizing PD-(L)1–Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings
Within RCC, bladder cancer, and NSCLC, next-generation PD-(L)1 combinations are reshaping treatment across all disease stages, and the magnitude of benefit, the relevant biomarkers, and the toxicity trade-offs differ substantially by tumor type and by setting.
F. Petrelli, Lara Colombo Zefinetti, A. D'Alessio et al.
· Current Oncology Reports · 0 citations